Chronic Hepatitis B Clinical Trial
Verified date | January 2017 |
Source | Yonsei University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
According to the World Health Organization about 1,400,000 deaths reported annually, are
related to chronic liver disease. Chronic liver disease is very prevalent in South Korea,
placing a large economic burden nationwide. Subsequently, an effective and systematized
approach to managing chronic hepatitis is imperative in Korea.
The natural history of chronic liver disease differs greatly according to race and
ethnicity. However, there is scarcity of epidemic data on chronic hepatitis based on Korean
patients. Therefore, the investigators plan to establish a retrospective and prospective
multicenter cohort for chronic hepatitis B based on Korean patients that may be utilized for
various future clinical studies on chronic hepatitis B in Korea, and thereby serve as a
basis for the establishment and distribution of clinical guidelines for Korean patients with
chronic hepatitis B, as part of a nationwide project supported by the Centers for Disease
Control (CDC), Korea.
The investigators plan to collect 500 cases as have been advised by the CDC during the study
period (September, 2014-March, 2015) from 4 tertiary hospitals located in Korea. In the past
5 years, there have been about 800 subjects with chronic hepatitis B who have undergone
liver fibroscan and liver biopsy from these 4 institutions. The investigators plan to
register available cases retrospectively from those who are available to agree to give
written informed consent to participate in this study, and to register the remaining numbers
of cases prospectively, according to the inclusion and exclusion criteria.
Status | Completed |
Enrollment | 476 |
Est. completion date | June 25, 2015 |
Est. primary completion date | June 25, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: 1. Subject aged 20 years or older 2. Subject who has been diagnosed with chronic hepatitis B (HBs Ag (+) for minimum of 6 months_ 3. Subject who is currently under clinical follow up at the registered institution 4. Subject who has undergone or who can undergo liver fibroscan at the time of registration 5. Subject who has given informed consent to the enrollment Exclusion Criteria: 1. Subject with decompensated liver cirrhosis or hepatocellular carcinoma at the time of initial liver fibroscan 2. Subject who had previously undergone antiviral therapy for chronic hepatitis B 3. Subject who are concomittantly infected with HCV, HDV or HIV 4. Subject with chronic alcoholism defined as equal to or greater than 40g of alcohol for duration of 5 years or longer 5. Subject who has been diagnosed with right sided heart failure 6. Subjects whose liver fibroscan result is not valid 7. Subject who is considered ineligible to the enrollment to clinical study by the researcher 8. Subjects who is pregnant at the time of registration 9. Pregnancy |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Yonsei University |
Jung KS, Kim SU, Ahn SH, Park YN, Kim DY, Park JY, Chon CY, Choi EH, Han KH. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011 Mar;53(3):885-94. doi: 10.1002/hep.24121. — View Citation
Kim SU, Ahn SH, Park JY, Kang W, Kim DY, Park YN, Chon CY, Han KH. Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis. J Clin Gastroenterol. 2009 Mar;43(3):267-71. doi: 10.1097/MCG.0b013e31816f212e. — View Citation
Kim SU, Seo YS, Cheong JY, Kim MY, Kim JK, Um SH, Cho SW, Paik SK, Lee KS, Han KH, Ahn SH. Factors that affect the diagnostic accuracy of liver fibrosis measurement by Fibroscan in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2010 Aug;32(3):498-505. doi: 10.1111/j.1365-2036.2010.04353.x. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | retrospective and prospective multicenter cohort for chronic hepatitis B based on Korean patients | This study aims for the establishment of chronic hepatitis B cohort and has no other primary end point other than the registration of the patient. (For Time-to-Event outcome measures, the development of events including HCC, ascitic decompensation, variceal bleeding, hepatic encephalopathy, transplantation, and death will be followed up to 10 years after enrollment. Time to the development of each kind of event will be calculated from the date of enrollment and the respective date of event development.) | time of registration of patient to cohort completment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04496882 -
Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue
|
Phase 4 | |
Completed |
NCT04083716 -
A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults
|
Phase 1 | |
Not yet recruiting |
NCT03038802 -
A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection
|
Phase 1/Phase 2 | |
Completed |
NCT05310487 -
Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects
|
Phase 1 | |
Recruiting |
NCT06070051 -
Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy
|
Phase 1 | |
Terminated |
NCT05001022 -
A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects
|
Phase 1 | |
Recruiting |
NCT04139850 -
The Establishment of Korean Hepatitis B Patients Cohort
|
||
Recruiting |
NCT05343481 -
Efficacy of VTP-300 in Chronic Hepatitis B Infection
|
Phase 2 | |
Not yet recruiting |
NCT05490836 -
Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients
|
N/A | |
Recruiting |
NCT04543565 -
Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study
|
Phase 3 | |
Active, not recruiting |
NCT02894918 -
A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs
|
Phase 4 | |
Not yet recruiting |
NCT02793791 -
Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients
|
N/A | |
Recruiting |
NCT02287857 -
Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B
|
N/A | |
Recruiting |
NCT01965418 -
A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial
|
Phase 4 | |
Recruiting |
NCT01491295 -
Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients
|
Phase 4 | |
Terminated |
NCT01872988 -
Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma
|
Phase 3 | |
Recruiting |
NCT01487876 -
Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients
|
Phase 2 | |
Completed |
NCT01531166 -
A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon
|
N/A | |
Not yet recruiting |
NCT01436539 -
Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients
|
Phase 4 | |
Recruiting |
NCT01360892 -
Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography
|
N/A |